Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 5, 2011, Pages 1244-1254

  López Guisa, Jesús M ^a   Rassa, Allen C ^a   Cai, Xiaohe ^a   Collins, Sarah J ^a   Eddy, Allison A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; Myofibroblasts; PAI 1; v integrin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD68 ANTIGEN; COLLAGEN; HYDROXYPROLINE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; UROKINASE; VITRONECTIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FIBROGENESIS; GENOTYPE; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; URETER OBSTRUCTION;

EID: 79955772903     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00701.2010     Document Type: Article

References (56)

1. Bariety J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD. Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol 75: 76-81, 1989.
2. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923-1930, 2010.
3. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100: 1481-1487, 1997.
4. Dahlback K, Lofberg H, Dahlback B. Immunohistochemical demonstration of vitronectin in association with elastin and amyloid deposits in human kidney. Histochemistry 87: 511-515, 1987.
5. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263: 15454-15461, 1988.
6. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 279: 22595-22604, 2004.
7. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571, 1996.
8. Eddy AA, Fogo AB. PAI-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17: 2999-3012, 2006.
9. Eklund AG, Sigurdardottir O, Ohrn M. Vitronectin and its relationship to other extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis. Am Rev Respir Dis 145: 646-650, 1992.
10. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 5: 864-868, 1993.
11. Francischetti IM, Kotsyfakis M, Andersen JF, Lukszo J. Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin. PloS One 5: e9356, 2010.
12. Hafdi Z, Lesavre P, Nejjari M, Halbwachs-Mecarelli L, Droz D, Noel LH. Distribution of alphavbeta3, alphavbeta5 integrins and the integrin associated protein-IAP (CD47) in human glomerular diseases. Cell Adhes Commun 7: 441-451, 2000.
13. Hafdi Z, Lesavre P, Tharaux PL, Bessou G, Baruch D, Halbwachs-Mecarelli L. Role of alpha v integrins in mesangial cell adhesion to vitronectin and von Willebrand factor. Kidney Int 51: 1900-1907, 1997.
14. Hermann A, Braun A, Figueroa CD, Muller-Esterl W, Fritz H, Rehbock J. Expression and cellular localization of kininogens in the human kidney. Kidney Int 50: 79-84, 1996.
15. Holmes R. Preparation from human serum of an alpha-one protein which induces the immediate growth of unadapted cells in vitro. J Cell Biol 32: 297-308, 1967.
16. Huang Y, Border WA, Lawrence DA, Noble NA. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in ex-perimental nephritis. Am J Physiol Renal Physiol 297: F1045-F1054, 2009.
17. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003.
18. Inuzuka S, Ueno T, Torimura T, Tamaki S, Sugawara H, Sakata R, Kusaba N, Sata M, Tanikawa K. The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol 32: 1052-1060, 1997.
19. Isik FF, Gibran NS, Jang YC, Sandell L, Schwartz SM. Vitronectin decreases microvascular endothelial cell apoptosis. J Cell Physiol 175: 149-155, 1998.
20. Jang YC, Tsou R, Gibran NS, Isik FF. Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery 127: 696-704, 2000.
21. Kamikubo Y, Neels JG, Degryse B. Vitronectin inhibits plasminogen activator inhibitor-1-induced signaling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor- related protein. Int J Biochem Cell Biol 41: 578-585, 2009.
22. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 103: 576-583, 2001.
23. Koukoulis GK, Shen J, Virtanen I, Gould VE. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum Pathol 32: 1356-1362, 2001.
24. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62: 748-751, 1989.
25. Lygoe KA, Norman JT, Marshall JF, Lewis MP. AlphaV integrins play an important role in myofibroblast differentiation. Wound Repair Regen 12: 461-470, 2004.
26. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177: 927-939, 2007.
27. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67: 2221-2238, 2005.
28. Murphy BF, Davies DJ, Morrow W, d'Apice AJ. Localization of terminal complement components S-protein and SP-40,40 in renal biopsies. Pathology 21: 275-278, 1989.
29. Norman JT, Fine LG. Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol 7: 167-177, 1999.
30. Oda T, Jung YO, Kim H, Cai X, Lopez-Guisa J, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 30: 587-596, 2001.
31. Ogawa T, Yorioka N, Yamakido M. Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy. Nephron 68: 87-96, 1994.
32. Okada M, Yoshioka K, Takemura T, Akano N, Aya N, Murakami K, Maki S. Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor. Virchows Arch 422: 367-373, 1993.
33. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501-1511, 2009.
34. Phipps JA, Feener EP. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int 73: 1114-1119, 2008.
35. Rahman S, Patel Y, Murray J, Patel KV, Sumathipala R, Sobel M, Wijelath ES. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signaling pathway in endothelial cells. BMC Cell Biol 6: 8, 2005.
36. Reilly JT, Nash JR. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J Clin Pathol 41: 1269-1272, 1988.
37. Schar CR, Jensen JK, Christensen A, Blouse GE, Andreasen PA, Peterson CB. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 283: 28487-28496, 2008.
38. Schoppet M, Chavakis T, Al-Fakhri N, Kanse SM, Preissner KT. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab Invest 82: 37-46, 2002.
39. Shiiki H, Nishino T, Uyama H, Kimura T, Nishimoto K, Hashimoto T, Fujii Y, Dohi K. Alterations in extracellular matrix components and integrins in patients with preeclamptic nephropathy. Virchows Arch 427: 567-573, 1996.
40. Shikata K, Makino H, Morioka S, Kashitani T, Hirata K, Ota Z, Wada J, Kanwar YS. Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 25: 680-688, 1995.
41. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Biol 11: 23-36, 2010.
42. Stefansson S, Lawrence DA. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE 2003: pe24, 2003.
43. Upton Z, Webb H, Hale K, Yandell CA, McMurtry JP, Francis GL, Ballard FJ. Identification of vitronectin as a novel insulin-like growth factor-II binding protein. Endocrinology 140: 2928-2931, 1999.
44. Van Dixhoorn MG, Salazar-Exaire D, Sato T, Daha MR, Quigg RJ, Bruijn JA, Couser WG, De Heer E. Anti-vitronectin antibodies enhance anti-Thy-1-induced proteinuria in PVG/c, but not in Wistar rats. J Am Soc Nephrol 9: 994-1007, 1998.
45. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regu-lating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100: 58-67, 1997.
46. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388, 1994.
47. Wun TC, Palmier MO, Siegel NR, Smith CE. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin. J Biol Chem 264: 7862-7868, 1989.
48. Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA. Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 293: F12-F19, 2007.
49. Yamaguchi I, Yamada M, Tchao BN, Burger M, Nicosia RF, Eddy AA. Structural and functional changes to renal peritubular capillaries after unilateral ureteral obstruction in mice. J Am Soc Nephrol 20: TH-PO115, 2009.
50. Yoon S, Gingras D, Bendayan M. Alterations of vitronectin and its receptor alpha(v) integrin in the rat renal glomerular wall during diabetes. Am J Kidney Dis 38: 1298-1306, 2001.
51. Zhang G, Cai X, Lopez-Guisa JM, Collins SJ, Eddy AA. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. J Am Soc Nephrol 15: 2090-2102, 2004.
52. Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci 13: 5462-5478, 2008.
53. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, Shvil Y, Eddy AA. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 18: 846-859, 2007.
54. Zhang G, Kim H, Cai X, Lopez-Guisa J, Alpers C, Liu Y, Carmeliet P, Eddy A. Urokinase receptor deficiency accelerates fibrosis in obstructive nephropathy. J Am Soc Nephrol 14: 1254-1271, 2003.
55. Zhang G, Kim H, Cai X, Lopez-Guisa J, Carmeliet P, Eddy A. Urokinase receptor modulates cellular and angiogenic responses in obstructive uropathy. J Am Soc Nephrol 14: 1234-1253, 2003.
56. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 92: 12426-12430, 1995.